We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.095 | -0.34% | 27.935 | 27.905 | 27.91 | 28.165 | 27.85 | 28.12 | 52,215 | 11:11:44 |
From May 2023 to May 2024
By Sabela Ojea
Bayer said Friday the Food and Drug Administration has approved its Ultravist injection to visualize breast lesions as an adjunct to mammographies or ultrasounds.
The pharmaceutical company said Ultravist-300 and -370 gives physicians a new imaging option beyond conventional mammographies.
"The new FDA-approved indication aligns with the recent increased focus on supplemental imaging needs for women at a higher risk for breast cancer," Bayer said.
Ultravist is an injection for intravenous and intra-arterial use.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
June 23, 2023 14:21 ET (18:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
